Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
| Status: | Terminated |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 12/22/2017 |
| Start Date: | November 2007 |
| End Date: | February 18, 2008 |
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
To assess the efficacy and safety of an investigational compound PF-02545920 for the
treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing
symptoms associated with schizophrenia.
treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing
symptoms associated with schizophrenia.
Inclusion Criteria:
1. Have a current diagnosis of schizophrenia.
2. Increase in symptoms over the past 2-4 weeks.
3. Willing to remain inpatients for the duration of the trial.
Exclusion Criteria:
1. Evidence or history of clinically significant medical problems.
2. Females of childbearing potential.
3. A primary psychiatric diagnosis other than schizophrenia.
4. A diagnosis of substance abuse or dependence in the last 6 months.
We found this trial at
10
sites
2 Church Street South
New Haven, Connecticut 06519
New Haven, Connecticut 06519
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials